Allergan Finance, LLC
Allergan Finance, LLC, a prominent player in the pharmaceutical and biotechnology industry, is headquartered in the United States. Founded in 1983, the company has established itself as a leader in the development of innovative medical aesthetics, eye care, and neuroscience products. With a strong presence in North America and Europe, Allergan Finance is renowned for its flagship offerings, including the popular Botox® treatment and a range of dermal fillers. The company has achieved significant milestones, including its acquisition by AbbVie in 2020, which further solidified its market position. Allergan Finance is committed to advancing healthcare solutions that enhance patient outcomes, making it a trusted name in the industry. Its unique focus on both aesthetic and therapeutic applications sets it apart, ensuring a diverse portfolio that meets the evolving needs of healthcare professionals and patients alike.
DitchCarbon Score
How does Allergan Finance, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergan Finance, LLC's score of 35 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allergan Finance, LLC's reported carbon emissions
Allergan Finance, LLC, headquartered in the US, currently does not have available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of information suggests that Allergan Finance may still be in the early stages of formalising its climate commitments or reporting on its emissions. In the context of the pharmaceutical industry, companies are increasingly expected to adopt robust sustainability practices and set measurable targets to reduce their carbon footprint. As such, Allergan Finance's future climate strategies will be crucial in aligning with industry standards and addressing global climate challenges.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Allergan Finance, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
